Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
CRIS Stock Chart & Stats
$1.25
-$0.29(-7.77%)
At close: 4:00 PM EST
$1.25
-$0.29(-7.77%)
Day’s Range― - ―
52-Week Range$1.02 - $4.70
Previous CloseN/A
Volume44.55K
Average Volume (3M)68.01K
Market Cap
$18.25M
Enterprise Value$51.62M
Total Cash (Recent Filing)$9.05M
Total Debt (Recent Filing)$30.60M
Price to Earnings (P/E)―
Beta2.73
Next Earnings
Mar 17, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding12,498,853
10 Day Avg. Volume74,344
30 Day Avg. Volume68,010
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.22
Price to Sales (P/S)1.77
P/FCF Ratio-0.49
Enterprise Value/Market Cap2.83
Enterprise Value/Revenue4.43
Enterprise Value/Gross Profit4.45
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$11.00Price Target Upside780.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development StrategyThe company remains focused on advancing its lead asset, emavusertib, a potential first-in-class oral, small molecule inhibitor of IRAK4, through clinical development.
Clinical Trials And ApplicationEmavusertib is being evaluated in ongoing Phase 1/2 clinical trials for Non-Hodgkins Lymphoma, acute myeloid leukemia, and as an add-on agent in frontline AML, highlighting its wide potential application.
Research ExpansionThe company recently added a clinical study of emavusertib in combination with a BTKi in Chronic Lymphocytic Leukemia (CLL), targeting enrollment of 20-30 patients with the goal of improving upon the current standard of care.
Bears Say
Clinical Trial RisksKey risks include clinical trial failure, efficacy in limited patient types, and failure to expand the drug development pipeline.
Financial RisksManagement expects the current cash runway to fund existing operations in 1Q26, supported by recent financing.
Curis News
CRIS FAQ
What was Curis Inc’s price range in the past 12 months?
Curis Inc lowest stock price was $1.02 and its highest was $4.70 in the past 12 months.
What is Curis Inc’s market cap?
Curis Inc’s market cap is $18.25M.
When is Curis Inc’s upcoming earnings report date?
Curis Inc’s upcoming earnings report date is Mar 17, 2026 which is in 109 days.
How were Curis Inc’s earnings last quarter?
Curis Inc released its earnings results on Nov 06, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.578 by $0.088.
Is Curis Inc overvalued?
According to Wall Street analysts Curis Inc’s price is currently Undervalued.
Does Curis Inc pay dividends?
Curis Inc does not currently pay dividends.
What is Curis Inc’s EPS estimate?
Curis Inc’s EPS estimate is -0.43.
How many shares outstanding does Curis Inc have?
Curis Inc has 12,498,853 shares outstanding.
What happened to Curis Inc’s price movement after its last earnings report?
Curis Inc reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.578. Following the earnings report the stock price went up 2.817%.
Which hedge fund is a major shareholder of Curis Inc?
Currently, no hedge funds are holding shares in CRIS
Company Description
Curis Inc
Curis, Inc. (CRIS) is a biotechnology company focused on the development of innovative drug therapies for the treatment of cancer. The company specializes in the discovery and development of targeted medicines, primarily focusing on small molecule drug candidates that modulate specific signaling pathways in cancer cells. Curis operates within the oncology sector, aiming to provide effective solutions for patients with various types of cancer through its proprietary drug development programs and collaborations with other pharmaceutical companies.
CRIS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical studies and reduced financial losses compared to the previous year. However, concerns about limited cash reserves and some dose-limiting toxicities in the AML triplet study were noted. Overall, the sentiment leans towards positive due to the promising clinical results and improved financial performance.View all CRIS earnings summariesCRIS Stock 12 Month Forecast
Average Price Target
$11.00
▲(780.00% Upside)
Technical Analysis
Bio Green Med Solution
―
Moleculin Biotech
―
Pulmatrix
―
Elevation Oncology
―
Rallybio
―
Ownership Overview
9.19%
Insiders
3.00% Mutual Funds
24.54% Other Institutional Investors
60.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---